Eponemycin exerts its antitumor effect through the inhibition of proteasome function

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2798-2801

  Meng, Lihao ^a   Kwok, Benjamin H B ^a   Sin, Ny ^a   Crews, Craig M ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROEPONEMYCIN; EPONEMYCIN; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; THYMOMA;

AMIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CATTLE; CELL CYCLE; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; MICE; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; SERINE;

EID: 0033564512     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hilt, W., and Wolf, D. H. Proteasomes: destruction as a programme. Trends Biochem. Sci., 21: 96-102, 1996.
2. Pamer, E., and Cresswell, P. Mechanisms of MHC class 1-restricted antigen processing. Annu. Rev. Immunol., 16: 323-358, 1998.
3. Monaco, J. J., and Nandi, D. The genetics of proteasomes and antigen processing. Annu. Rev. Genet., 29: 729-754, 1995.
4. Palombella, V. J., Rando, O. J., Goldberg, A. L., and Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell, 78: 773-785, 1994.
5. King, R. W., Deshaies, R. J., Peters, J. M., and Kirschner, M. W. How proteolysis drives the cell cycle. Science (Washington DC), 274: 1652-1659, 1996.
6. Rolfe, M., Chiu, M. I., and Pagano, M. The ubiquitin-mediated proteolytic pathway as a therapeutic area. J. Mol. Med., 75: 5-17, 1997.
7. Spataro, V., Norbury, C., and Harris, A. L. The ubiquitin-proteasome pathway in cancer. Br. J. Cancer, 77: 448-455, 1998.
8. Sin, N., Meng, L., Auth, H., and Crews, C. M. Eponemycin analogs: synthesis and use as probes of angiogenesis. Bioorg. Med. Chem., 6: 1209-1217, 1998.
9. Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., and Schreiber, S. L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (Washington DC), 268: 726-731, 1995.
10. Sugawara, K., Hatori, M., Nishiyama, Y., Tomita, K., Kamei, H., Konishi, M., and Oki, T. Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J. Antibiot. (Tokyo), 43: 8-18, 1990.
11. Oikawa, T., Hasegawa, M., Shimamura, M., Ashino, H., Murota. S., and Morita, I. Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitor. Biochem. Biophys. Res. Commun., 181: 1070-1076, 1991.
12. Früh, K., Yang, Y., Arnold, D., Chambers, J., Wu, L., Waters, J. B., Spies, T., and Peterson, P. A. Alternative exon usage and processing of the major hislocompatibility complex-encoded proteasome subunits. J. Biol. Chem., 267: 22131-22140, 1992.
13. Lee, D. H., and Goldberg, A. L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol., 8: 397-403, 1998.
14. Fenteany, G., and Schreiber, S. L. Lactacystin, proteasome function, and cell fate. J. Biol. Chem., 273: 8545-8548, 1998.
15. Dick, L. R., Cruikshank, A. A., Grenier, L., Melandri, F. D., Nunes, S. L., and Stein, R. L. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J. Biol. Chem., 271: 7273-7276, 1996.
16. Gaczynska, M., Rock, K. L., and Goldberg, A. L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature (Lond.), 365: 264-267, 1993.
17. Spaltenstein, A., Leban, J. J., Huang, J. J., Reinhardt, K. R., Viveros, O. H., Sigafoos, J., and Crouch, R. Design and synthesis of novel protease inhibitors. Tripeptide α′,β′-epoxyketones as nanomolar inactivators of the proteasome. Tetrahedron Lett., 37: 1343-1346, 1996.
18. Fenteany, G., and Schreiber, S. L. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem. Biol., 3: 905-912, 1996.
19. Fujita, E., Mukasa, T., Tsukahara, T., Arahata, K., Omura, S., and Momoi, T. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors. Biochem. Biophys. Res. Commun., 224: 74-79, 1996.
20. Soldatenkov, V. A., and Dritschilo, A. Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res., 57: 3881-3885, 1997.
21. Imajoh-Ohmi, S., Kawaguchi, T., Sugiyama, S., Tanaka, K., Omura, S., and Kikuchi, H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem. Biophys. Res. Commun., 217: 1070-1077, 1995.
22. Delic, J., Masdehors, P., Omura, S., Cosset, J. M., Dumont, J., Binet, J. L., and Magdelenat, H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br. J. Cancer, 77: 1103-1107, 1998.
23. Orlowski, R. Z., Eswara, J. R., Lafond-Walker, A., Grever, M. R., Orlowski, M., and Dang, C. V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res., 58: 4342-4348, 1998.